Status:

UNKNOWN

The Development of Human Papillomavirus Type 16 E7-Specific Human Immunologic Assays in Non-HLA2 Type Human Being

Lead Sponsor:

National Taiwan University Hospital

Conditions:

Cervical Cancer

Eligibility:

FEMALE

18-80 years

Brief Summary

Cervical cancer the most frequent neoplasm and the third mortality rate of malignancies of the women in the world. It results in about 200,000 women dying of cervical cancer each year worldwide. The a...

Detailed Description

HPV and Cervical Cancers Human papillomaviruses (HPV) are small, nonenveloped DNA viruses which induce epithelial tumors of skin or mucosa. The majority of tumors are benign, show limited growth and u...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • normal volunteer, patients with CIN lesions or cervical cancers whose HLA haplotype is not HLA-A2

Exclusion

    Key Trial Info

    Start Date :

    January 1 2002

    Trial Type :

    OBSERVATIONAL

    End Date :

    December 1 2006

    Estimated Enrollment :

    300 Patients enrolled

    Trial Details

    Trial ID

    NCT00155792

    Start Date

    January 1 2002

    End Date

    December 1 2006

    Last Update

    December 20 2005

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    National Taiwan University Hospital

    Taipei, Taiwan

    The Development of Human Papillomavirus Type 16 E7-Specific Human Immunologic Assays in Non-HLA2 Type Human Being | DecenTrialz